Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Analysts have given Alnylam Pharmaceuticals an average price target of $436.

The heart-drug developer sent a new signal to biotech investors about what Wall Street is willing to fund in 2026. That is ...

It has been a banner year for biotech buyouts, and these are two of the prime targets.

That is a big risk investors take when trying to find the winners and losers within the biotech sector. While we made the ...

In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in ...

Biotech investors are finally getting something they haven't seen in years: a friendlier macro environment. Interest rates appear to be stabilizing, FDA activity is picking up again, and large ...

Shares of Profusa (PFSA) hit a record low on Thursday, crashing 28% after the biotech company announced its second reverse ...

Biotechnology is enjoying one of its strongest years in recent times, which is mostly fueled by a rebound in capital markets, ...

Shares of French biotech company Abivax soared Tuesday after it released fresh data on its lead drug for bowel disease.